ProShare Advisors’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-62,249
| Closed | -$558K | – | 1787 |
|
|
2016
Q3 | $558K | Sell |
62,249
-11,713
| -16% | -$83.3K | 0.01% | 907 |
|
|
2016
Q2 | $397K | Buy |
73,962
+1,012
| +1% | +$5.19K | 0.01% | 1069 |
|
|
2016
Q1 | $336K | Sell |
72,950
-7,206
| -9% | -$29K | ﹤0.01% | 1154 |
|
|
2015
Q4 | $417K | Buy |
80,156
+10,564
| +15% | +$61.3K | 0.01% | 1126 |
|
|
2015
Q3 | $421K | Sell |
69,592
-4,870
| -7% | -$59.7K | 0.01% | 991 |
|
|
2015
Q2 | $1.18M | Buy |
74,462
+6,881
| +10% | +$83.6K | 0.02% | 702 |
|
|
2015
Q1 | $735K | Buy |
67,581
+12,038
| +22% | +$123K | 0.01% | 999 |
|
|
2014
Q4 | $584K | Sell |
55,543
-1,663
| -3% | -$16.2K | 0.01% | 1123 |
|
|
2014
Q3 | $549K | Sell |
57,206
-11,323
| -17% | -$116K | 0.01% | 1344 |
|
|
2014
Q2 | $792K | Sell |
68,529
-38,781
| -36% | -$353K | 0.01% | 1284 |
|
|
2014
Q1 | $1.07M | Buy |
107,310
+75,966
| +242% | +$1.1M | 0.01% | 1255 |
|
|
2013
Q4 | $408K | Sell |
31,344
-27,295
| -47% | -$376K | 0.01% | 1092 |
|
|
2013
Q3 | $876K | Buy |
58,639
+11,990
| +26% | +$144K | 0.02% | 974 |
|
|
2013
Q2 | $436K | Buy |
+46,649
| New | +$316K | 0.01% | 1432 |
|
ProShare Advisors's RPTP Position: Q4 2016 in Review
ProShare Advisors sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 62,249 shares — an estimated $558K sold.
ProShare Advisors first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $1.18M in Q2 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.
- ProShare Advisors reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
- ProShare Advisors sold 62,249 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $558K.
- ProShare Advisors first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 14 quarters.
- ProShare Advisors's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $1.18M in Q2 2015.
- 0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.
Based on ProShare Advisors's 13F filing for Q4 2016, filed 13 Feb 2017.